Abstract
I read with interest the article by Boden et al. (1) regarding the prevention of fluid retention with the use of fenofibrate in combination with rosiglitazone. Impressive clinical data has recently been published on the use of thiazolidinedione (TZD) therapy for diabetes, but the increased incidence of edema and heart failure has been viewed as a major concern …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
